This page shows the latest AAT deficiency news and features for those working in and with pharma, biotech and healthcare.
treat the genetic disease alpha 1 antitrypsin (AAT) deficiency.
Blaine Forshage, Shire's US immunology franchise lead, commented that patients with AAT deficiency “are managing a challenging disorder that may require regular regimented care”. ... Chronically under-diagnosed, only an estimated 10% of the 100, 000
52 . Kamada/Baxter. Glassia (liquid Alpha-1 Antitrypsin; AAT) – AAT deficiency (US, Canada, Australia and New Zealand) . FDA approved. 45. Marina Biotech/Cypress Bioscience. Carbetocin (nasal oxytocin analogue) - autism.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
No results were found
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...